Literature DB >> 21498509

Multiple transmembrane binding sites for p-trifluoromethyldiazirinyl-etomidate, a photoreactive Torpedo nicotinic acetylcholine receptor allosteric inhibitor.

Ayman K Hamouda1, Deirdre S Stewart, S Shaukat Husain, Jonathan B Cohen.   

Abstract

Photoreactive derivatives of the general anesthetic etomidate have been developed to identify their binding sites in γ-aminobutyric acid, type A and nicotinic acetylcholine receptors. One such drug, [(3)H]TDBzl-etomidate (4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzyl-[(3)H]1-(1-phenylethyl)-1H-imidazole-5-carboxylate), acts as a positive allosteric potentiator of Torpedo nACh receptor (nAChR) and binds to a novel site in the transmembrane domain at the γ-α subunit interface. To extend our understanding of the locations of allosteric modulator binding sites in the nAChR, we now characterize the interactions of a second aryl diazirine etomidate derivative, TFD-etomidate (ethyl-1-(1-(4-(3-trifluoromethyl)-3H-diazirin-3-yl)phenylethyl)-1H-imidazole-5-carboxylate). TFD-etomidate inhibited acetylcholine-induced currents with an IC(50) = 4 μM, whereas it inhibited the binding of [(3)H]phencyclidine to the Torpedo nAChR ion channel in the resting and desensitized states with IC(50) values of 2.5 and 0.7 mm, respectively. Similar to [(3)H]TDBzl-etomidate, [(3)H]TFD-etomidate bound to a site at the γ-α subunit interface, photolabeling αM2-10 (αSer-252) and γMet-295 and γMet-299 within γM3, and to a site in the ion channel, photolabeling amino acids within each subunit M2 helix that line the lumen of the ion channel. In addition, [(3)H]TFD-etomidate photolabeled in an agonist-dependent manner amino acids within the δ subunit M2-M3 loop (δIle-288) and the δ subunit transmembrane helix bundle (δPhe-232 and δCys-236 within δM1). The fact that TFD-etomidate does not compete with ion channel blockers at concentrations that inhibit acetylcholine responses indicates that binding to sites at the γ-α subunit interface and/or within δ subunit helix bundle mediates the TFD-etomidate inhibitory effect. These results also suggest that the γ-α subunit interface is a binding site for Torpedo nAChR negative allosteric modulators (TFD-etomidate) and for positive modulators (TDBzl-etomidate).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498509      PMCID: PMC3121496          DOI: 10.1074/jbc.M111.219071

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm.

Authors:  Guosheng Wu; Daniel H Robertson; Charles L Brooks; Michal Vieth
Journal:  J Comput Chem       Date:  2003-10       Impact factor: 3.376

2.  Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.

Authors:  Toby Collins; Neil S Millar
Journal:  Mol Pharmacol       Date:  2010-05-12       Impact factor: 4.436

3.  Multiple affinity states for noncompetitive blockers revealed by [3H]phencyclidine binding to acetylcholine receptor rich membrane fragments from Torpedo marmorata.

Authors:  R E Oswald; T Heidmann; J P Changeux
Journal:  Biochemistry       Date:  1983-06-21       Impact factor: 3.162

4.  p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.

Authors:  S Shaukat Husain; Deirdre Stewart; Rooma Desai; Ayman K Hamouda; S Guo-Dong Li; Elizabeth Kelly; Zuzana Dostalova; Xiaojuan Zhou; Joseph F Cotten; Douglas E Raines; Richard W Olsen; Jonathan B Cohen; Stuart A Forman; Keith W Miller
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

5.  2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.

Authors:  S Shaukat Husain; Michael R Ziebell; Dirk Ruesch; Filbert Hong; Enrique Arevalo; Jonathan A Kosterlitz; Richard W Olsen; Stuart A Forman; Jonathan B Cohen; Keith W Miller
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

6.  Numerous classes of general anesthetics inhibit etomidate binding to gamma-aminobutyric acid type A (GABAA) receptors.

Authors:  Guo-Dong Li; David C Chiara; Jonathan B Cohen; Richard W Olsen
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

7.  Conformational changes in the nicotinic acetylcholine receptor during gating and desensitization.

Authors:  Innocent H Yamodo; David C Chiara; Jonathan B Cohen; Keith W Miller
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

8.  Identification of binding sites in the nicotinic acetylcholine receptor for [3H]azietomidate, a photoactivatable general anesthetic.

Authors:  Michael R Ziebell; Selvanayagam Nirthanan; S Shaukat Husain; Keith W Miller; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2004-02-03       Impact factor: 5.157

9.  Structure and gating mechanism of the acetylcholine receptor pore.

Authors:  Atsuo Miyazawa; Yoshinori Fujiyoshi; Nigel Unwin
Journal:  Nature       Date:  2003-06-26       Impact factor: 49.962

10.  Identification of nicotinic acetylcholine receptor amino acids photolabeled by the volatile anesthetic halothane.

Authors:  David C Chiara; Lawrence J Dangott; Roderic G Eckenhoff; Jonathan B Cohen
Journal:  Biochemistry       Date:  2003-11-25       Impact factor: 3.162

View more
  30 in total

1.  Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation.

Authors:  Corrie J B daCosta; Chris R Free; Jeremías Corradi; Cecilia Bouzat; Steven M Sine
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

2.  Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Authors:  Ayman K Hamouda; Ze-Jun Wang; Deirdre S Stewart; Atul D Jain; Richard A Glennon; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2015-04-13       Impact factor: 4.436

3.  Identifying barbiturate binding sites in a nicotinic acetylcholine receptor with [3H]allyl m-trifluoromethyldiazirine mephobarbital, a photoreactive barbiturate.

Authors:  Ayman K Hamouda; Deirdre S Stewart; David C Chiara; Pavel Y Savechenkov; Karol S Bruzik; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2014-02-21       Impact factor: 4.436

4.  Mechanisms revealed through general anesthetic photolabeling.

Authors:  Brian P Weiser; Kellie A Woll; William P Dailey; Roderic G Eckenhoff
Journal:  Curr Anesthesiol Rep       Date:  2014-03-01

5.  Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses.

Authors:  Ze-Jun Wang; Farah Deba; Tasnim S Mohamed; David C Chiara; Kara Ramos; Ayman K Hamouda
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

6.  A photoreactive analog of allopregnanolone enables identification of steroid-binding sites in a nicotinic acetylcholine receptor.

Authors:  Zhiyi Yu; David C Chiara; Pavel Y Savechenkov; Karol S Bruzik; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2019-03-28       Impact factor: 5.157

7.  Stoichiometry for drug potentiation of a pentameric ion channel.

Authors:  Corrie J B daCosta; Steven M Sine
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

8.  Common Anesthetic-binding Site for Inhibition of Pentameric Ligand-gated Ion Channels.

Authors:  Monica N Kinde; Weiming Bu; Qiang Chen; Yan Xu; Roderic G Eckenhoff; Pei Tang
Journal:  Anesthesiology       Date:  2016-03       Impact factor: 7.892

Review 9.  Shedding Light on Anesthetic Mechanisms: Application of Photoaffinity Ligands.

Authors:  Kellie A Woll; William P Dailey; Grace Brannigan; Roderic G Eckenhoff
Journal:  Anesth Analg       Date:  2016-11       Impact factor: 5.108

10.  Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric Modulator.

Authors:  Ayman K Hamouda; Farah Deba; Ze-Jun Wang; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2016-03-14       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.